Biomarin Pharmaceutical Inc BMRN
We take great care to ensure that the data presented and summarized in this overview for BIOMARIN PHARMACEUTICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BMRN
View all-
Black Rock Inc. New York, NY22.7MShares$1.36 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.13 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.06 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$892 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$644 Million2.55% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.15MShares$546 Million0.15% of portfolio
-
State Street Corp Boston, MA8.46MShares$505 Million0.03% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN4.21MShares$251 Million0.08% of portfolio
-
Paul Singer Elliott Investment Management L.P. | West Palm Beach, Fl3.5MShares$209 Million1.66% of portfolio
-
Geode Capital Management, LLC Boston, MA3.43MShares$205 Million0.02% of portfolio
Latest Institutional Activity in BMRN
Top Purchases
Top Sells
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Transactions at BMRN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 20
2025
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+4.96%
|
-
|
May 20
2025
|
Timothy P Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+40.47%
|
-
|
May 20
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,155
-6.59%
|
$127,145
$59.93 P/Share
|
May 20
2025
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.92%
|
-
|
May 20
2025
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+19.19%
|
-
|
May 20
2025
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+13.71%
|
-
|
May 20
2025
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.91%
|
-
|
May 20
2025
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+32.92%
|
-
|
May 20
2025
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+14.58%
|
-
|
May 20
2025
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,650
+16.18%
|
-
|
May 20
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,786
-11.19%
|
$105,374
$59.31 P/Share
|
May 19
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
996
-5.87%
|
$58,764
$59.27 P/Share
|
May 02
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
273
-0.83%
|
$17,472
$64.92 P/Share
|
Apr 30
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
273
+0.82%
|
$14,742
$54.14 P/Share
|
Mar 19
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,295
-7.1%
|
$91,945
$71.52 P/Share
|
Mar 17
2025
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,940
+13.5%
|
-
|
Mar 17
2025
|
Erin Burkhart GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,970
+24.65%
|
-
|
Mar 17
2025
|
Cristin Hubbard EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,310
+28.93%
|
-
|
Mar 17
2025
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,310
+14.14%
|
-
|
Mar 17
2025
|
Gregory R Friberg EVP, Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,750
+27.49%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 307K shares |
---|
Payment of exercise price or tax liability | 92.5K shares |
---|---|
Open market or private sale | 17.7K shares |